NeuroSense rises on approval in Germany to enroll patients in mid-stage ALS trial

Neurosense Therapeutics

08/02/2023 14:49

** Shares of NeuroSense Therapeutics Ltd  NRSN.O  rise 18.6%
to $1.82
    ** The Israel-based drug developer receives approval in
Germany to enroll patients in its mid-stage Amyotrophic lateral
sclerosis (ALS) trial
    ** Expects to enroll the first study participant in Germany
in the next few weeks
    ** NRSN says on track to complete enrollment and report data
in the second half of this year
    ** ALS is a progressive nervous system disease that affects
nerve cells in the brain and spinal cord, causing loss of muscle
control
    ** Co lost 50% in 2022
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))